CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
© 2021. The Author(s)..
High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail frequent dose-refinement for optimal immunosuppression. In heart transplant recipients, the contribution of patients' CYP3A-status (CYP3A5 genotype and CYP3A4 expression) to tacrolimus blood concentration and dose-requirement was evaluated in the early and late post-operative period. In low CYP3A4 expressers carrying CYP3A5*3/*3, the dose-corrected tacrolimus level was significantly higher than in normal CYP3A4 expressers or in those with CYP3A5*1. Modification of the initial tacrolimus dose was required for all patients: dose reduction by 20% for low CYP3A4 expressers, a 40% increase for normal expressers and a 2.4-fold increase for CYP3A5*1 carriers. The perioperative high-dose corticosteroid therapy was assumed to ameliorate the low initial tacrolimus-metabolizing capacity during the first month. The fluctuation of CYP3A4 expression and tacrolimus blood concentration (C0/D) was found to be associated with tapering and cessation of corticosteroid in CYP3A5 non-expressers, but not in those carrying CYP3A5*1. Although monitoring of tacrolimus blood concentration cannot be omitted, assaying recipients' CYP3A-status can guide optimization of the initial tacrolimus dose, and can facilitate personalized tacrolimus therapy during steroid withdrawal in the late post-operative period.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Scientific reports - 11(2021), 1 vom: 01. Nov., Seite 21389 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Déri, Máté [VerfasserIn] |
---|
Links: |
---|
Themen: |
CYP3A5 protein, human |
---|
Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-021-00942-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332636321 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM332636321 | ||
003 | DE-627 | ||
005 | 20231226203805.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-021-00942-y |2 doi | |
028 | 5 | 2 | |a pubmed24n1108.xml |
035 | |a (DE-627)NLM332636321 | ||
035 | |a (NLM)34725418 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Déri, Máté |e verfasserin |4 aut | |
245 | 1 | 0 | |a CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.01.2022 | ||
500 | |a Date Revised 24.01.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail frequent dose-refinement for optimal immunosuppression. In heart transplant recipients, the contribution of patients' CYP3A-status (CYP3A5 genotype and CYP3A4 expression) to tacrolimus blood concentration and dose-requirement was evaluated in the early and late post-operative period. In low CYP3A4 expressers carrying CYP3A5*3/*3, the dose-corrected tacrolimus level was significantly higher than in normal CYP3A4 expressers or in those with CYP3A5*1. Modification of the initial tacrolimus dose was required for all patients: dose reduction by 20% for low CYP3A4 expressers, a 40% increase for normal expressers and a 2.4-fold increase for CYP3A5*1 carriers. The perioperative high-dose corticosteroid therapy was assumed to ameliorate the low initial tacrolimus-metabolizing capacity during the first month. The fluctuation of CYP3A4 expression and tacrolimus blood concentration (C0/D) was found to be associated with tapering and cessation of corticosteroid in CYP3A5 non-expressers, but not in those carrying CYP3A5*1. Although monitoring of tacrolimus blood concentration cannot be omitted, assaying recipients' CYP3A-status can guide optimization of the initial tacrolimus dose, and can facilitate personalized tacrolimus therapy during steroid withdrawal in the late post-operative period | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a CYP3A5 protein, human |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Tacrolimus |2 NLM | |
650 | 7 | |a WM0HAQ4WNM |2 NLM | |
700 | 1 | |a Szakál-Tóth, Zsófia |e verfasserin |4 aut | |
700 | 1 | |a Fekete, Ferenc |e verfasserin |4 aut | |
700 | 1 | |a Mangó, Katalin |e verfasserin |4 aut | |
700 | 1 | |a Incze, Evelyn |e verfasserin |4 aut | |
700 | 1 | |a Minus, Annamária |e verfasserin |4 aut | |
700 | 1 | |a Merkely, Béla |e verfasserin |4 aut | |
700 | 1 | |a Sax, Balázs |e verfasserin |4 aut | |
700 | 1 | |a Monostory, Katalin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 11(2021), 1 vom: 01. Nov., Seite 21389 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:01 |g month:11 |g pages:21389 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-00942-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 1 |b 01 |c 11 |h 21389 |